Esoterix Expands Molecular Diagnostics Testing Capability; Company Introduces Two New Innovative and Dynamic Molecular Diagnostics Testing Products, HCVExact and CFDetx.Business Editors/Health/Medical Writers AUSTIN, Texas--(BUSINESS WIRE)--Dec. 2, 2003 Esoterix, a leading laboratory services company, today announced the completion of a new molecular diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease center, and the introduction of two new molecular diagnostics testing products, HCVExact(TM) and CFDetx(TM). New Molecular Diagnostic Testing Center in California Esoterix has completed the development of a new, state-of-the-art molecular diagnostic testing center in their Calabasas Hills, CA facility. As a result, Esoterix will now offer a broad range of molecular based diagnostic assays at the company's main West Coast laboratory. This molecular facility will create expanded testing capabilities for Esoterix and will also deliver improvements in assay performance, sample handling, and turnaround times. Introducing New Hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. Assay - HCVExact Esoterix has launched HCVExact, a highly sensitive Adj. 1. highly sensitive - readily affected by various agents; "a highly sensitive explosive is easily exploded by a shock"; "a sensitive colloid is readily coagulated" assay that measures the virus level in hepatitis C patients. This assay provides physicians with a superior tool to assess the severity of the disease and to monitor therapy. HCVExact, utilizing the TaqMan(TM) Real Time-PCR based methodology, will offer the broadest dynamic range in the industry. With Esoterix's rapid turnaround time and serial reporting format, physicians using HCVExact can deliver improved patient care and better assess response to treatment. Introducing CFDetx For Cystic Fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. Carrier Screening or Diagnosis Esoterix has launched CFDetx, a mutation analysis for cystic fibrosis carrier screening or diagnosis. Cystic fibrosis is one of the most common terminal autosomal-recessive disorders in the Caucasian population. It is now recommended that couples who are pregnant, or considering pregnancy, should be screened for this disease. Esoterix's CFDetx provides a comprehensive analysis of common cystic fibrosis mutations, including the 25 mutations recommended by both the American College of Medical Genetics The American College of Medical Genetics (ACMG) is an organization composed of biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors and other health care professionals committed to the practice of medical genetics. and the American College of Obstetricians and Gynecologists The American College of Obstetricians and Gynecologists (ACOG) is a professional association of medical doctors specializing in obstetrics and gynecology in the United States. It has a membership of over 49,000[1] and represents 90 percent of U.S. . James A. McClintic, president and chief executive officer, stated, "We have experienced tremendous growth in our molecular testing business over the past few years. Our new West Coast molecular laboratory, combined with new testing capabilities in the rapidly growing hepatitis C and cystic fibrosis markets, will position Esoterix for continued substantial molecular testing growth. We are excited to be at the forefront of molecular diagnostics and plan to continue to invest in this growth area." Esoterix is a leading laboratory services company focused on high science, superior customer service, and innovative new products. With annual revenues in excess of $100 million and over 750 employees, Esoterix offers approximately 2,500 assays and profiles through its centers of excellence in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Western Europe Western Europe The countries of western Europe, especially those that are allied with the United States and Canada in the North Atlantic Treaty Organization (established 1949 and usually known as NATO). . Esoterix's extensive client base includes hospitals, physicians, pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. , reference laboratories, and managed care organizations. For more information on Esoterix, please visit http://www.esoterix.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion